Clinical Trial Update: Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

View source ↗

Summary

Expanded access study for brexucabtagene autoleucel (Tecartus) for mantle cell lymphoma and acute lymphoblastic leukemia is currently available, sponsored by Ki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Mantle Cell Lymphoma

Drugs mentioned

• Tecartus (brexucabtagene autoleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia | Status: AVAILABLE